Organization and Basis of Presentation (Tables)

3 Months Ended

Mar. 31, 2026

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Schedule of Company's Consolidated Statements of Operations

The table below shows a reconciliation of the Company’s net loss, including the significant expense categories regularly provided to and

reviewed by the CODM, as computed under U.S. GAAP to the Company’s total consolidated net loss in the Consolidated Statements of Operations:

	For the Three Months Ended March 31,
	2026			2025
Sales	$	30,893		$	37,895
Cost of sales		7,395			9,566
Gross profit		23,498			28,329
Operating expenses:
Commercial		20,210			21,174
General and administrative		11,645			7,462
Research and development		7,836			9,056
Clinical & regulatory		1,636			1,311
Total operating expenses		41,327			39,003
Loss from operations		(17,829	)		(10,674	)
Other income (expense), net:
Interest expense		(3	)		(6	)
Interest and other income		1,954			2,508
Loss before income taxes		(15,878	)		(8,172	)
Income tax expense		6			18
Net loss	$	(15,884	)	$	(8,190	)